Monthly Intel

Consilium Strategic Communications February Newsletter 2017

Consilium Strategic Communications February Newsletter 2017

STATE OF THE NATION - 2017 

Kate Bingham, Managing Partner, SV Life Sciences, shares her view of the industry, diversity and dementia research

 

Kate, congratulations on your awards over the past year and your work with SVLS and the Dementia Discovery Fund. You are a vocal commentator on the industry; what one change would you like to happen in the next five years?

I’m not sure I’ve got a single change but I would like to see a UK company developing a blockbuster and staying independent. We have created blockbusters but we have yet to properly capitalise on that with a UK-based company.

Consilium Strategic Communications January Newsletter 2017

Consilium Strategic Communications January Newsletter 2017

In deciding where to locate your research-based biopharmaceutical company, the probability of success in developing your compounds and bringing them through to commercialisation is key. The regulatory framework of your chosen market plays a vital role in determining this success.

Post the UK referendum, increased uncertainty has entered the equation, challenging the confidence of potential investors in the UK. What will happen when the UK leaves the EU? Can the EMA remain in the UK?

Consilium Strategic Communications December Newsletter 2016

Consilium Strategic Communications December Newsletter 2016

The 2016 Consilium Strategic Communications, Covington and RBC Capital Markets Annual Healthcare Conference was more successful than ever with more than 230 delegates in attendance. Following a day of insightful discussion, the key takeaway was that the healthcare industry can weather current political storms and seize opportunities to create strong investment opportunities for years to come.

 

Consilium Strategic Communications October Newsletter 2016

Consilium Strategic Communications October Newsletter 2016

Last month the FDA granted accelerated approval for Sarepta’s EXONDYS 51™ (eteplirsen) drug for the treatment of Duchenne muscular dystrophy (DMD) following an intense patient advocacy campaign. We spoke to Marc Pentopoulos, fund manager and consultant from Symmetry Capital Management, about the power of US patient groups given his experience in the area.

Consilium Strategic Communications September Newsletter 2016

Consilium Strategic Communications September Newsletter 2016

Consilium Strategic Communications will host its Annual Healthcare Conference in association with Covington & Burling LLP and RBC Capital Markets. This invitation-only half-day event will take place during the afternoon of 15 November 2016 at 8 Eastcheap, London, EC3M 1AE, from 12.30pmconcluding with a drinks reception from 5.30pm to 7pm with speaker dinner thereafter.

Consilium Strategic Communications July/August Newsletter 2016

Consilium Strategic Communications July/August Newsletter 2016

Consilium advises on early preparation for JP Morgan week  San Francisco

January 2017

Consilium Strategic Communications June Newsletter 2016

Consilium Strategic Communications June Newsletter 2016

The biggest challenge in my job is to explain complex biomedical technologies in ways which the lay reader can understand but without oversimplifying the science, or introducing inaccuracies into the story. Generally speaking, I think companies do a great job in explaining this and making it accessible. I find the sector endlessly stimulating and it keeps me continually busy.

Consilium Strategic Communications May Newsletter 2016

Consilium Strategic Communications May Newsletter 2016

Footprint Cafés and a Queen’s Award FOR Enterprise Promotion

Last month, Consilium Strategic Communications helped support the launch of a new charity, Footprint Cafés, a chain of sustainable cafés targeted at the developing world. 

Consilium Strategic Communications April Newsletter 2016

Consilium Strategic Communications April Newsletter 2016

The healthcare sector has suffered as companies have encountered a more challenging reimbursement environment generally, and particularly in the US,
which has historically shouldered more than its fair share of pharmaceutical costs.

Consilium Strategic Communications March Newsletter 2016

Consilium Strategic Communications March Newsletter 2016

Interview with Carl Sterritt: Founder and CEO of Shield Therapeutics plc

Consilium Strategic Communications February Newsletter 2016

Consilium Strategic Communications February Newsletter 2016

An interview with Denise Roland, Pharmacuticals reporter 

 
  1 2   

Careers

Join us at Consilium

Consilium Strategic Communications welcomes prospective candidates and interns to share a copy of their résumé and a cover letter via email.

Sign up

Register for news and updates

   
logo

Design By Brandcast Media